Ebos lifted profit 21% in FY22 but analysts are asking how long it can last

Ebos lifted profit 21% in FY22 but analysts are asking how long it can last
Chief executive John Cullity said covid could be a tailwind or a headwind by the end of FY23. (Photo: Ebos)
Dan Brunskill
Ebos Group’s annual revenue has climbed above A$10 billion (NZ$11.15b) as the pandemic has increased demand for pharmaceutical products, but analysts are asking if that trend could reverse.  The healthcare and animal products company has been a beneficiary of the covid-19 pandemic, growing its revenue from A$8.7b in 2020 to A$10.7b in 2022.This year alone it grew revenue by 16.6%, underlying earnings by 19% and underlying net profit by 21.3% to A$228.2 million.Not all the growth has been driven by the pandemic however, Forsyth Barr r...

More Markets

NZ sharemarket rises with gentailers leading
Markets Market close

NZ sharemarket rises with gentailers leading

Electricity gentailers pumped energy into the NZX.

Tom Raynel 09 May 2025
Steven Joyce to chair NZME
Markets

Steven Joyce to chair NZME

Tech expert Bowen Pan will also join, later on. 

Staff reporters 09 May 2025
NZME set to take on Trade Me for car sales
Markets

NZME set to take on Trade Me for car sales

Publicly listed NZME, owner of the NZ Herald and BusinessDesk, says it is exploring a new automotive digital classifieds platform, in a clear bid to take on Trade Me.Seeking to emulate the success of its property platform OneRoof, NZME said on Friday it had signed a memorandum of...

Staff reporters 09 May 2025
Bremworth getting back into synthetics
Primary Sector

Bremworth getting back into synthetics

Albeit in a small, but carefully curated, number of products.

Riley Kennedy 09 May 2025